144 related articles for article (PubMed ID: 3561327)
21. Screening for neuroblastoma in France: methodological aspects and preliminary observations.
Chauvin F; Mathieu P; Frappaz D; Lasset C; Favrot MC; Greffe J; Esteve J; Thiesse P; Combaret V; Chauvot P; Boschetti R; David L; Brunat-Mentigny M; Philip T
Med Pediatr Oncol; 1997 Feb; 28(2):81-91. PubMed ID: 8986143
[TBL] [Abstract][Full Text] [Related]
22. Mass screening for neuroblastoma and mortality in birth cohorts.
Nishi M; Miyake H; Takeda T; Hanai J; Kikuchi Y; Takasugi N
Int J Cancer; 1997 May; 71(4):552-5. PubMed ID: 9178807
[TBL] [Abstract][Full Text] [Related]
23. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children.
Bessho F; Hashizume K; Nakajo T; Kamoshita S
J Pediatr; 1991 Aug; 119(2):237-41. PubMed ID: 1861208
[TBL] [Abstract][Full Text] [Related]
24. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
25. Mass-screening of neuroblastoma using urine from infants by high-performance liquid chromatographic method: results of first (6th month) and second (14th month) screening.
Takeda T; Shimada M; Nishi M; Hanai J; Kikuchi Y
J Neurooncol; 1997 Jan; 31(1-2):165-70. PubMed ID: 9049845
[TBL] [Abstract][Full Text] [Related]
26. Mass screening for neuroblastoma in Japan. Committee of the Neuroblastoma Mass Screening Study of the Japanese Society of Pediatric Oncology.
Sawada T; Nagahara N; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Okawa H; Tsunoda A; Sakurai M
Acta Paediatr Jpn; 1990 Dec; 32(6):725-33. PubMed ID: 2082676
[TBL] [Abstract][Full Text] [Related]
27. Vanillylmandelic acid, homovanillic acid, and catecholamines in urine of infants with neuroblastoma 6- to 11-month-old.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1986 Dec; 16(4):351-5. PubMed ID: 3795531
[TBL] [Abstract][Full Text] [Related]
28. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution.
Nishihira H; Toyoda Y; Tanaka Y; Ijiri R; Aida N; Takeuchi M; Ohnuma K; Kigasawa H; Kato K; Nishi T
J Clin Oncol; 2000 Aug; 18(16):3012-7. PubMed ID: 10944135
[TBL] [Abstract][Full Text] [Related]
29. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
Okazaki T; Kohno S; Mimaya J; Hasegawa S; Urushihara N; Yoshida A; Kawano S; Kusafuka J; Horikoshi Y; Takashima Y; Aoki K; Hamazaki M
Pediatr Surg Int; 2004 Jan; 20(1):27-32. PubMed ID: 14689211
[TBL] [Abstract][Full Text] [Related]
30. A population-based study of the usefulness of screening for neuroblastoma.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
[TBL] [Abstract][Full Text] [Related]
31. Which cases are found and missed by neuroblastoma screening at 1 year? Results from the 1992 to 1995 study in three Federal States of Germany.
Berthold F; Baillot A; Hero B; Schurr P; Nerenz A; Hunneman DH; Sander J
J Clin Oncol; 1999 Apr; 17(4):1200. PubMed ID: 10561179
[TBL] [Abstract][Full Text] [Related]
32. Screening for neuroblastoma in the northern region of England. Laboratory aspects.
Seviour JA; McGill AC; Craft AW; Parker L; Bell S; Cole M; Smith J; Hawkins E; Brown J; Dale GA
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):332-6. PubMed ID: 1456399
[TBL] [Abstract][Full Text] [Related]
33. Biochemical screening for neuroblastoma in infants: a feasibility study.
Craft AW; Dale G; McGill A; Seviour J; Spence EM
Med Pediatr Oncol; 1989; 17(5):373-8. PubMed ID: 2796853
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.
Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M
Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578
[TBL] [Abstract][Full Text] [Related]
35. Neuroblastoma screening in the United States: results of the Texas Outreach Program for neuroblastoma screening.
Ater JL; Gardner KL; Foxhall LE; Therrell BL; Bleyer WA
Cancer; 1998 Apr; 82(8):1593-602. PubMed ID: 9554539
[TBL] [Abstract][Full Text] [Related]
36. Imaging evaluation of infants with neuroblastoma detected by VMA screening spot test.
Fujioka M; Saiki N; Aihara T; Yamamoto K
Pediatr Radiol; 1988; 18(6):479-83. PubMed ID: 3054769
[TBL] [Abstract][Full Text] [Related]
37. The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: A descriptive study.
Shinagawa T; Kitamura T; Katanoda K; Matsuda T; Ito Y; Sobue T
Int J Cancer; 2017 Feb; 140(3):618-625. PubMed ID: 27778323
[TBL] [Abstract][Full Text] [Related]
38. Effects of mass screening on age-specific incidence of neuroblastoma.
Bessho F
Int J Cancer; 1996 Aug; 67(4):520-2. PubMed ID: 8759611
[TBL] [Abstract][Full Text] [Related]
39. [The "Lower Saxony/Northern Rhine-Westphalia" Neuroblastoma Screening Project: on the need for epidemiologic comparison].
Berthold F; Sander J; Baillot A; Hunneman DH; Michaelis J
Klin Padiatr; 1992; 204(4):288-92. PubMed ID: 1518267
[TBL] [Abstract][Full Text] [Related]
40. Screening for neuroblastoma and age-specific incidence.
Moe PJ
Acta Paediatr; 1999 Apr; 88(4):362-4. PubMed ID: 10342530
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
